Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month

The transcript discusses Merck's new drug for a rare skin cancer, priced at $13,000 a month, and its significance in the market. The drug has received FDA breakthrough designation for bladder cancer and is part of Merck's focus on immuno-oncology. Merck is also selling its biosimilars business, indicating a strong pipeline of innovative products. The company is confident in the US market's support for innovation despite ongoing discussions about drug pricing.

What advancements has Merck made in the field of immuno-oncology over the past few years?

What is the current status of Merck's biosimilars business and its future focus?